Haley Melikian
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Haley Melikian is a Professor at the University of Massachusetts Medical School in the United States. Her research focuses on dopamine transporter trafficking and the mechanisms of action involving Rit2 GTPase, as highlighted in her recent articles. Her work contributes to the understanding of neurobiology and transport mechanisms in vivo.
Recent Grants
Grant: Close
Dopamine Transporter: Tools for in vivo molecular replacement
Open Date: 2020-04-01
Close Date: 2022-03-01
Grant: Close
Trafficking and Regulation of Monoamine Transporters
Open Date: 2002-05-01
Close Date: 2018-08-31
Articles (4)
The dopamine (DA) transporter (DAT) is a major determinant of DAergic neurotransmission, and is a primary target for addictive and therapeutic psychostimulants. Evidence accumulated over decades in cell lines and in vitro preparations revealed that DAT function is acutely regulated by membrane trafficking. Many of these findings have recently been validated in vivo and in situ, and several behavioral and physiological findings raise the possibility that regulated DAT trafficking may impact DA signaling and DA‐dependent behaviors. Here we review key DAT trafficking findings across multiple systems, and discuss the cellular mechanisms that mediate DAT trafficking, as well as the endogenous receptors and signaling pathways that drive regulated DAT trafficking. We additionally discuss recent findings that DAT trafficking dysfunction correlates to perturbations in DA signaling and DA‐dependent behaviors. image
Year:
2024
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease and arises from dopamine (DA) neuron death selectively in the substantia nigra pars compacta (SNc). Rit2 is a reported PD risk allele, and recent single cell transcriptomic studies identified a major RIT2 cluster in PD DA neurons, potentially linking Rit2 expression loss to a PD patient cohort. However, it is still unknown whether Rit2 loss itself impacts DA neuron function and/or viability. Here we report that conditional Rit2 silencing in mouse DA neurons drove motor dysfunction that occurred earlier in males than females and was rescued at early stages by either inhibiting the DA transporter (DAT) or with L-DOPA treatment. Motor dysfunction was accompanied by decreased DA release, striatal DA content, phenotypic DAergic markers, DA neurons, and DAergic terminals, with increased pSer129-alpha synuclein and pSer935-LRRK2 expression. These results provide clear evidence that Rit2 loss is causal for SNc cell death and motor dysfunction, and reveal key sex-specific differences in the response to Rit2 loss.
Year:
2024
Year:
2020
Year:
2020
Collaborators (1)
Zhenyu Yue
Professor
Icahn School of Medicine at Mount Sinai
Make your next move.
Prepare your application
Review drafts before you send them.